2Bartenschlager R.The NS3/4A proteinase of the hepatitis C virus:unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy.J Viral Hepat,1999,6:165-181.
3Butkiewicz N,Yao N,Zhong W,et al.Virus-specific cofactor requirement and chimeric hepatitis C virus/GB virus B nonstructural protein 3.J Virol,2000,74:4291-4301.
4Lin C,Wu JW,Hsiao K,et al.The hepatitis C virus NS4A protein:interactions with the NS4B and NS5A proteins.J Virol,1997,71:6465-6471.
5Wright-Minogue J,Yao N,Zhang R,et al.Cross-genotypic interaction between hepatitis C virus NS3 protease domains and NS4A cofactors.J Hepatol,2000,32:497-504.
6Zemel R,Gerechet S,Greif H,et al.Cell transformation induced by hepatitis C virus NS3 serine protease.J Viral Hepat,2001,8:96-102.
7Kneteman NM,Weiner AJ,O' Connell J,el al.Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application.Hepatology,2006,43:1346-1353.
8Hinrichsen H,Benhamou Y,Wedemeyer H,et al.Short-term antiviral efficacy of BILN 2061,a hepatitis C virus serine protease inhibitor,in hepatitis C genotype 1 patients.Gastroenterology,2004,127:1347-1355.
9Reiser M,Hinrichsen H,Benhamou Y,et al.Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.Hepatology,2005,41:832-835.
10Tong X,Guo Z,Wright-Minogue J,et al.Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors.Biochemistry,2006,45:1353-1361.
5Kuo G,Choo QL,Alter HJ,et al.An assay for circulating anti-bodies to a major etiologic virus of human non-A,non-B hepatitis[J].Science,1989,244:362-364.
6Tuke PW,Grant PR,Waite J,et al.Hepatitis C viruswindow2phase infections:closing the window on hepatitis sC virus[J].Transfusion,2008,48(4):594-600.
7Grakoui A,McCourt D W,Wychowski C,et al.Characterization of the hepa2titis C virus Encoded serine proteinase:determination of proteinase dependedpolyprotein cleavage sites[J].Journal of Virology,1993,67:2832-2839.
8Kim D W,Gwack Y,Han J H,et al.C terminal domain of the hepatitis Cvirus NS3 protein contains an RNA helicase activity[J].Biochem Biophy ResCommun,1995,215:160-165.
9VENKATRAMAN S, BOGEN S L, ARASAPPAN A, et al. Discovery of ( 1R,5 S ) -N- [ 3 -amino-I - (cyclobutylmethyl) -2, 3-dioxopropyl ] -3- [ 2 ( S ) - [ [ [ ( 1,1 -dimethylethyl ) amino ] carbonyl ] amino ] -3,3-dimethyl-1 -oxobutyl ] -6,6-dimethyl-3- azabicyclo [ 3.1.0 ] hexan-2 ( S ) -carboxamide ( SCH503034 ), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection [ J ]. J Med Chem, 2006,49 ( 20 ) : 6074 - 6086.
